Bill C-393 (Historical)

An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act

This bill is from the 40th Parliament, 3rd session, which ended in March 2011.

Sponsor

Paul Dewar  NDP

Introduced as a private member’s bill. (These don’t often become law.)

Status

Second reading (Senate), as of March 24, 2011
(This bill did not become law.)

Summary

This is from the published bill.

This enactment amends the Patent Act to make it easier to manufacture and export pharmaceutical products to address public health problems afflicting many developing and least-developed countries, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics.

Similar bills

C-398 (41st Parliament, 1st session) An Act to amend the Patent Act (drugs for international humanitarian purposes)
S-208 (41st Parliament, 1st session) An Act to amend the Patent Act and the Food and Drugs Act (drugs for international humanitarian purposes)
C-393 (40th Parliament, 2nd session) An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act
S-232 (40th Parliament, 2nd session) An Act to amend the Patent Act (drugs for international humanitarian purposes) and to make a consequential amendment to another Act

Elsewhere

All sorts of information on this bill is available at LEGISinfo, an excellent resource from Parliament. You can also read the full text of the bill.

Bill numbers are reused for different bills each new session. Perhaps you were looking for one of these other C-393s:

C-393 (2024) An Act to amend the Canadian Environmental Protection Act, 1999 (electronic products recycling program)
C-393 (2018) An Act to amend the Canadian Multiculturalism Act (non-application in Quebec)
C-393 (2013) Railway Noise and Vibration Control Act
C-393 (2012) Railway Noise and Vibration Control Act

Votes

March 9, 2011 Passed That Motion No. 3 be amended by deleting all the words after the words “The provisions of this Act that amend the Patent Act” and substituting the following: “shall cease to apply on the day that is the tenth anniversary of the day on which this Act comes into force unless, before that day, the application of those provisions is subject to a comprehensive review by the standing committee designated by the House of Commons for that purpose, that committee recommends that they be maintained and the House of Commons approves that recommendation.”.

Industry, Science and Technology Committee, on Oct. 7, 2010

  • Colette Downie, Director General, Marketplace Framework Policy Branch, Industry Canada
  • Louise Clément, Senior Director, Regional and Geographic Programs - Southern and Eastern Africa, Canadian International Development Agency
  • Robert Ready, Chief Air Negotiator, Department of Foreign Affairs and International Trade
  • Brigitte Zirger, Director, Policy Bureau, Therapeutic Products Directorate, Health Products and Food Branch, Department of Health
  • Christine Reissmann, Director, AIDS, TB Programming and Health Institutions, Multilateral and Global Programs Branch, Canadian International Development Agency

Industry, Science and Technology Committee, on Oct. 21, 2010

  • Richard Elliott, Executive Director, Canadian HIV/AIDS Legal Network
  • Don Kilby, President and Founder, Canada Africa Community Health Alliance

Industry, Science and Technology Committee, on Oct. 26, 2010

  • Richard Dearden, Partner, Gowlings, As an Individual
  • Rachel Kiddell-Monroe, Chair, Universities Allied for Essential Medicines
  • Amir Attaran, Canada Research Chair, Law, Population Health, and Global Development Policy, University of Ottawa, As an Individual
  • Joshua Kimani, Canadian Medical Institute in Kenya, As an Individual
  • Frederick Abbott, Edward Ball Eminent Scholar, Professor of International Law, Florida State University College of Law, As an Individual
  • Linda Watson, Member, National Advocacy Committee of the Grandmothers to Grandmothers Campaign
  • Elizabeth Rennie, Member, National Advocacy Committee of the Grandmothers to Grandmothers Campaign
  • Angus Livingstone, Managing Director, University-Industry Liaison Office, University of British Columbia, As an Individual
  • Emilou MacLean, Director, United States of America, Campaign for Access to Essential Medicines, Doctors Without Borders
  • Grant Perry, Vice-President, Public Affairs/Reimbursement, GlaxoSmithKline Canada
  • Russell Williams, President, Canada's Research-Based Pharmaceutical Companies (Rx & D)
  • Laurence Dotto, Director, Government and External Affairs, Canada's Research-Based Pharmaceutical Companies (Rx & D)
  • Frank Plummer, Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada
  • Jim Keon, President, Canadian Generic Pharmaceutical Association
  • David Schwartz, Chair, Biotechnology Patents Committee, Intellectual Property Institute of Canada
  • Antony Taubman, Director, Intellectual Property Division, World Trade Organization (WTO)
  • Paula Akugizibwe, Advocacy Coordinator, AIDS and Rights Alliance for Southern Africa
  • Andrew Jenner, Director, Intellectual Property and Trade, International Federation of Pharmaceutical Manufacturers and Associations

Industry, Science and Technology Committee, on Oct. 28, 2010

  • Mona Frendo, Director, Patent and Trade-mark Policy Directorate, Department of Industry
  • Colette Downie, Director General, Marketplace Framework Policy Branch, Department of Industry
  • Mike MacPherson, Procedural Clerk
  • Rob Sutherland-Brown, Senior Counsel, Legal Services, Justice Canada, Department of Industry

Industry, Science and Technology Committee, on Nov. 1, 2010